Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.66 |
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | AHCY | P23526 | 2/20 | 0.57 |
| ▸ | FAP | Q12884 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608687 | 0.88 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL15257613 | 0.88 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL3305032 | 0.88 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| Water SCHEMBL28104561 | 0.86 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| Water SCHEMBL28104578 | 0.86 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL28062940 | 0.86 | CYP3A4 (0.60) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL18543643 | 0.86 | CYP3A4 (0.63) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL18543642 | 0.86 | CYP3A4 (0.63) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL10015788 | 0.86 | ADORA2A (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B | |
| SCHEMBL1249908 | 0.86 | ADORA2A (0.69) | CYP3A4ADORA2AADORA1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159574-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-05-25 | — | — | US | disclosed |
| WO-2021034804-A1 | PHARMACEUTICAL FORMULATIONS OF TENOFOVIR ALAFENAMIDE | GILEAD SCIENCES, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2020018399-A1 | PHOSPHINIC AMIDE PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2020-01-23 | — | — | WO | disclosed |
| WO-2018119013-A1 | ANTIVIRAL ALIPHATIC ESTER PRODRUGS OF TENOFOVIR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| EP-2928876-B1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2017203395-A1 | CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE HEMI FUMARATE | SHILPA MEDICARE LIMITED (IN) | 2017-11-30 | — | — | WO | disclosed |
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. | 2016-05-12 | — | — | US | disclosed |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2015-11-05 | — | — | US | disclosed |
| WO-2015108780-A1 | SOLID FORMS OF TENOFOVIR | GILEAD SCIENCES, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2014088923-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| WO-2013090420-A2 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244966-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | CYP3A4 2263/4885ADORA2A 645/4885ADORA1 1140/4885 |
| US-20140288025-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | CYP3A4 2263/4885ADORA2A 645/4885ADORA1 1140/4885 |
| US-20230159574-A1 | BENZYLOXY PHOSPH(ON)ATE COMPOUNDS | PYGL, GOT2, ALPI | CYP3A4 1046/4885ADORA2A 425/4885ADORA1 1154/4885 |
| US-20150315221-A1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | DCK, DTYMK, TK1 | CYP3A4 1852/4885ADORA2A 353/4885ADORA1 1092/4885 |
| US-20160129122-A1 | FATTY ACID ANTIVIRAL CONJUGATES AND THEIR USES | FABP1, FABP2, HAVCR2 | CYP3A4 2263/4885ADORA2A 645/4885ADORA1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.